Investigating arterial stiffening's role in heart failure with preserved ejection fraction
Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
This study is trying to see if measuring how stiff the arteries are can help identify people at risk for developing heart failure with preserved ejection fraction.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Medical Center Goettingen Academic / other |
| Locations | 1 site (Göttingen, Lower Saxony) |
| Trial ID | NCT06208007 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess patients at risk for developing heart failure with preserved ejection fraction (HFpEF) through structured clinical evaluations, transthoracic echocardiography, and pulse-wave analysis. The focus is on understanding how arterial stiffening may predict the onset of cardiac diastolic dysfunction and HFpEF. By identifying these associations, the study seeks to enhance early detection and management strategies for at-risk individuals.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals over 60 years old with conditions such as hypertension, diabetes, or obesity.
Not a fit: Patients with left ventricular ejection fraction below 50% or significant valve disease are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and management of heart failure with preserved ejection fraction in at-risk patients.
How similar studies have performed: While the specific approach of this study may be novel, previous studies have explored the relationship between arterial stiffness and heart failure, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: One or more of the following criteria: * Age \> 60 years * Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs) * Diabetes mellitus Type I or II * Atrial fibrillation * Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g) * BMI ≥ 30 kg/m2 * NYHA ≥ II * E/e' \> 8 Exclusion Criteria: * Left ventricular ejection fraction \< 50 % * Significant valve disease (Grade III or higher) * History of interventional or surgical valve repair * Regional wall motion abnormalities * Respiratory diseases as a known cause for dyspnea * Atrial flutter or fibrillation during examination * Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy * History of heart transplantation
Where this trial is running
Göttingen, Lower Saxony
- Universitätsmedizin Göttingen — Göttingen, Lower Saxony, Germany (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.